Treatment of visceral leishmaniasis in 2004

American Journal of Tropical Medicine and Hygiene

Volumn 71, Issue 6, 2004, Pages 787-794

  Murray, Henry W ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY; ANTIRETROVIRUS AGENT; B7 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPOKALEMIA; IMMUNOTHERAPY; KIDNEY FAILURE; NAUSEA; VISCERAL LEISHMANIASIS; VOMITING;

HUMAN IMMUNODEFICIENCY VIRUS; NASO HEXACANTHUS; PROTOZOA;

EID: 11344279997     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2004.71.787     Document Type: Article

References (27)

1. Yamey G, 2002. The world's most neglected diseases. BMJ 325: 176-177.
2. Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson ADM, 2002. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494-501.
3. Murray HW, 2002. Kala-azar - progress against a neglected disease. N Engl J Med 347: 1793-1794.
4. Murray HW, 2004. Progress in treatment of a neglected disease: visceral leishmaniasis. Expert Rev Anti-Infect Ther 2: 279-292.
5. Murray HW, 2001. Clinical and experimental advances in treatment in visceral leishmaniasis. Antimicrob Agents Chemother 45: 2185-2197.
6. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PCK, Murray HW, 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1106.
7. Gradoni L, Bryceson A, Desjeux P, 1995. Treatment of Mediterranean visceral leishmaniasis. Bull World Health Organ 73: 191-197.
8. Gradoni L, Gramiccia M, Scalone A, 2003. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 9: 1617-1620.
9. Veeken H, Ritmeijer K, Seaman J, Davidson R, 2002. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for visceral leishmaniasis under field conditions in Sudan. Trop Meet Int Health 5: 312-317.
10. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A, 1999. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93: 319-323.
11. Sundar S, Mehta H, Sures AV, Singh SP, Rai M, Murray HW, 2004. Amphotericin B treatment for Indian visceral leishmaniasis: conventional vs. lipid-formulations. Clin Infect Dis 38: 377-383.
12. Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson ADM. 1998. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76: 25-32.
13. Dietze R, Fagundes S, Brito E, Milan EP, Feitosa TF, Suassuna FAB, Fonschiffrey G, Ksionski G, Dember J, 1995. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 89: 309-311.
14. Gaeta GB, Maisto A, Di Caprio D, Scalone A, Pasquale G, Felaco FM, Galante D, Gradoni L, 2000. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J Infect Dis 32: 675-677.
15. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2002. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 66: 143-146.
16. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW, 2001. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. BMJ 323: 419-422.
17. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R, 2003. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 37: 800-804.
18. Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulou I, Manolaki AG, Sereti E, Karamboula A, Papathanasiou D, Krikos X, Saroglou G, 2003. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 36: 560-566.
19. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, Singh NKP, Akhoury S, Jha S, 1998. Randomised controlled trial of aminosidine (paromomycin) v. sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 61: 1200-1205.
20. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J, 2002. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
21. Pagliano P, Rossi M, Rescigno C, Altieri S, Coppola MG, Gramiccia M, Scalone A, Gradoni L, Faella F, 2003. Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001). J Antimicrob Chemother 52: 264-268.
22. Pintado V, Martin-Rabadan P, Rivera ML, Morneo S, Bouza E, 2001. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80: 54-73.
23. Laguna F, 2003. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 97 (suppl 1): 135-142.
24. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, Seaman J, Davidson RN, 2001. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 95: 668-672.
25. Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, Reed SG, Jones TC, 1994. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 170: 413-418.
26. Croft SL, Coombs GH, 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
27. Demicheli C, Ochoa R, da Silva JB, Falcao C A, Rossi-Bergmann B, de Melo AL, Sinisterra RD, Frezard F, 2004. Oral delivery of meglumine antimonoate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob Agents Chemother 48: 100-103.